Veru Inc. (NASDAQ:VERU) Short Interest Up 278.5% in April

Veru Inc. (NASDAQ:VERUGet Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 10,940,000 shares, a growth of 278.5% from the March 31st total of 2,890,000 shares. Currently, 17.0% of the company’s stock are sold short. Based on an average trading volume of 15,920,000 shares, the days-to-cover ratio is presently 0.7 days.

A number of equities analysts have recently weighed in on VERU shares. HC Wainwright upped their price target on shares of Veru from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, April 12th. Zacks Investment Research downgraded shares of Veru from a “buy” rating to a “hold” rating in a research note on Thursday, April 21st. Oppenheimer upped their price target on shares of Veru from $25.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 12th. Finally, TheStreet downgraded shares of Veru from a “c-” rating to a “d” rating in a research note on Thursday, February 10th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $25.33.

Veru stock opened at $13.24 on Thursday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -66.20 and a beta of 0.49. Veru has a one year low of $4.34 and a one year high of $17.50. The company’s fifty day moving average price is $7.17 and its two-hundred day moving average price is $6.94.

Veru (NASDAQ:VERUGet Rating) last posted its earnings results on Wednesday, February 9th. The company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. The firm had revenue of $14.14 million for the quarter, compared to the consensus estimate of $17.24 million. Veru had a negative net margin of 26.68% and a negative return on equity of 10.62%. During the same period in the prior year, the business posted ($0.02) earnings per share. Equities research analysts forecast that Veru will post -0.34 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in VERU. Goldman Sachs Group Inc. grew its position in shares of Veru by 193.8% in the third quarter. Goldman Sachs Group Inc. now owns 321,868 shares of the company’s stock valued at $2,745,000 after purchasing an additional 212,314 shares during the last quarter. Millennium Management LLC boosted its stake in Veru by 407.1% during the 3rd quarter. Millennium Management LLC now owns 543,593 shares of the company’s stock valued at $4,637,000 after purchasing an additional 436,394 shares during the period. Metropolitan Life Insurance Co NY boosted its stake in Veru by 81.5% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 16,061 shares of the company’s stock valued at $137,000 after purchasing an additional 7,214 shares during the period. Creative Planning acquired a new stake in Veru in the 3rd quarter valued at approximately $141,000. Finally, Principal Financial Group Inc. bought a new position in Veru in the 3rd quarter worth approximately $97,000. Institutional investors own 30.42% of the company’s stock.

About Veru (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Read More

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.